Supplementary Figure 2 from Disrupting Protein NEDDylation with MLN4924 Is a Novel Strategy to Target Cisplatin Resistance in Ovarian Cancer
Steffan T. Nawrocki(University of Arizona), Jennifer S. Carew(University of Arizona), Allison Berger(Takeda (United States)), Sean A. Beausoleil(The University of Texas at San Antonio Health Science Center), Claudia M. Espitia(The University of Texas System), Peter G. Smith(Kenya Medical Research Institute), Michael A. Milhollen(Millennium Engineering and Integration (United States)), Anthony Possemato(Cell Signaling Technology (United States)), Kevin R. Kelly(Keck Hospital of USC), Michael Thomas, Stephen J. Blakemore(Epizyme (United States))
Cited by 0
Related Papers
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Survivin: Key Regulator of Mitosis and Apoptosis and Novel Target for Cancer Therapeutics
|Clinical Cancer Research|2008|782